Median Technologies' Eyonis LCS, an AI tool for low-dose CT lung cancer screening, receives FDA clearance.
Key Details
- 1Median Technologies received FDA clearance for Eyonis LCS, an AI/ML-powered computer-aided detection software as a medical device.
- 2Designed to assist in the interpretation of low-dose CT (LDCT) scans for lung cancer screening, addressing inter-reader variability.
- 3Eyonis LCS is reported as the first end-to-end FDA-cleared device specifically for lung cancer screening workflows.
- 4Performance testing showed 93.3% sensitivity, 92.4% specificity, and 99.9% negative predictive value (NPV).
- 5The tool is aimed at improving screening access and diagnostic accuracy, as well as reducing unnecessary procedures.
Why It Matters
FDA clearance for Eyonis LCS marks a significant advancement in AI-assisted lung cancer screening by leveraging CT imaging. The device's strong performance metrics and focus on workflow efficiency could help radiology practices meet increasing screening demands while improving patient outcomes.
Source
Radiology Business
Related News
•AuntMinnie
Stanford Launches Merlin: 3D AI Model for Abdominal CT Interpretation
Stanford researchers introduce Merlin, a 3D vision-language AI model for interpreting abdominal CT scans, demonstrating strong performance across multiple radiology tasks.
•Radiology Business
RadNet Acquires AI Firm Gleamer in $270M Deal to Expand Radiology Solutions
RadNet will acquire Gleamer for up to $270 million, aiming to make DeepHealth the largest global provider of radiology clinical AI solutions.
•Radiology Business
Real-World Study: AI Improves Breast Cancer Detection in 3D Mammography
AI use in breast radiology increased cancer detection without higher recall rates, according to a 100,000+ case multicenter study.